Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal
| 57.14 | 52-week high | +157.04% |
| 43.40 | Previous month high | +95.23% |
| 31.07 | Previous month low | +39.77% |
| 25.97 | Previous week high | +16.82% |
| 24.28 | R3 (classic) | +9.21% |
| 23.60 | R2 (classic) | +6.15% |
| 22.92 | Previous day high | +3.08% |
| 22.91 | R1 (classic) | +3.07% |
| 22.48 | Previous week low | +1.10% |
| 22.23 | Pivot | +0.01% |
| 22.23 | Price now | |
| 21.55 | Previous day low | −3.06% |
| 21.55 | S1 (classic) | −3.07% |
| 20.87 | S2 (classic) | −6.13% |
| 20.18 | S3 (classic) | −9.21% |
| 14.78 | 52-week low | −33.51% |
None of the 29 investors followed here reported a position in NBTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NBTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.2 | 47.8 | -0.5 | 12.1 | 16.7 | -6.7 | 1.8 | 5.9 | -23.3 | -28.7 | −3.8% | ||
| 2025 | 21.4 | 0.7 | 2.0 | -5.3 | 20.9 | 15.4 | 46.0 | 29.5 | 111.2 | 10.5 | -0.9 | 11.7 | +705.6% |
| 2024 | 4.4 | -17.8 | 4.0 | -10.2 | 20.5 | -29.0 | 8.4 | 10.7 | -4.2 | -27.7 | -22.4 | -11.1 | −60.6% |
| 2023 | 16.2 | -17.5 | 0.1 | -39.3 | 114.0 | 10.7 | 52.1 | 18.5 | -4.3 | -22.9 | -17.0 | 29.9 | +98.4% |
| 2022 | -5.6 | -1.4 | -1.3 | -20.7 | -11.4 | -27.3 | -38.9 | 72.0 | -11.3 | 11.9 | -0.3 | -7.1 | −54.7% |
| 2021 | 1.0 | -0.3 | -9.5 | 2.9 | 10.7 | -19.5 | 6.9 | -14.4 | -9.8 | -8.2 | -18.7 | -4.5 | −50.9% |
| 2020 | — |
No insider transactions reported for NBTX.
Buy / hold / sell counts
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.